This research study will seek to assign a specific drug treatment based upon pre-treatment characteristics of study subject's tumor obtained from biopsy material taken at the original diagnosis. Specifically, in this research study, they are observing to see how well bevacizumab and radiation, followed by bevacizumab with or without temozolomide and/or erlotinib, works on the study subject's tumor.
Bevacizumab is a commercially available drug that is FDA approved for the treatment of glioblastoma that has returned after treatment (recurrent glioblastoma). However, treatment with bevacizumab alone has only modestly improved survival in patients with this type of brain tumor. For this reason, researchers are evaluating other treatments, including bevacizumab combined with radiation.
The purpose of this study is to determine whether adding radiation to bevacizumab is more effective than using bevacizumab alone to treat recurrent glioblastomas. In this trial patients will be randomly assigned to receive either bevacizumab alone or bevacizumab and radiation therapy.
The purpose of this study is to:
? See if taking the study agent, armodafinil, at a dose of 150mg or 250mg, will improve problems with fatigue in patients who have been diagnosed with cancer and are experiencing fatigue.
? See the effects (good and bad) of taking Armodafinil compared to placebo (an inactive agent) on cancer related fatigue.
In this study, subjects will take either the study agent, armodafinil, or the placebo (inactive agent). They will not take both.
Armodafinil (Nuvigil®) is a medicine that is currently FDA approved to promote wakefulness in people who have sleep disorders. However, it is not been studied in people with cancer related fatigue.
This study is for patients that have been diagnosed with cancer, specifically a T-cell lymphoma. The investigational drug in this study is 4-HPR. The purpose of this study is to see what effects fenretinide will have on your tumor. Participants can expect to be in this study for up to two years.
Approximately 40 healthy male and female patients, ages 18 to 65, will participate in this study. The primary objective of the study is to evaluate the acceptability, tolerability, and efficacy of administering capsules with built-in, ingestible computer chips to healthy people The primary outcome will be medication compliance as measured by the proportion of days adherent to taking medication over a 30 day period.
This study is for patients that have been diagnosed with diffuse large B-cell lymphoma (DLBCL), which has never been treated. The drug in this study is brentuximab vedotin. The purpose of the first part of the study was to test the safety and effectiveness of 2 different doses of brentuximab vedotin when given with a combination of drugs called RCHOP [rituximab, cyclophosphamide, hydroxydaunorubicin (also called doxorubicin), vincristine (Oncovin), and prednisone]. The purpose of the second part of the study is to test the safety and effectiveness of brentuximab vedotin when given with a combination of drugs that does not include vincristine called RCHP [rituximab, cyclophosphamide, hydroxydaunorubicin (also called doxorubicin), and prednisone]. Participants can expect to be in this study for up to 2-3 years.
This study will evaluate the safety and effects of Lumacaftor (661) in combination with Ivacaftor (770) over 32 weeks in subjects with Cystic Fibrosis 6 to 11 years old who are homozygous for the F508del CFTR Mutation.
The study will consist of two treatment groups: active drug and placebo, with a optional rollover portion to receive active drug only after 24 weeks.
This study is for patients with von Willebrand Disease undergoing surgical procedures. The study drug, recombinant von Willebrand Factor, will be used with or without Advate (Factor VIII) in the pre-, peri-, and post- operative timeframe to prevent abnormal bleeding episodes. Participation in the study is expected to last 8-15 weeks.
This study is for patients that have been diagnosed with metastatic castration-resistant prostate cancer and have been previously treated with enzalutamide followed by docetaxel. This experimental study is being done to study the effectiveness and safety of enzalutamide when it is administered as re-treatment, following prior enzalutamide use and treatment with docetaxel. The length of time that patients are in the study will depend on their tolerance of the study medication and the state of their disease. They will continue in the study until they show signs of disease progression or unacceptable toxicity of the study medication.